Companies · Biotech / Pharma

Asset Blue Pharmacy Services, Inc.

CHICAGO · Biotech / Pharma · refined from filed group “Other

Diligence memoA one-page analyst read on Asset Blue Pharmacy Services, Inc. — recommendation, valuation, rhythm, risks.
$48.0M
Total raised · real
3
Rounds
0.6×
Latest step-up
Top 13%
Sector rank · raised
Series B
Latest stage · inferred · Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Asset Blue Pharmacy Services, Inc. looks under-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech/pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.40× the median modeled value of Series B Biotech / Pharma companies in 2022–2024 (15 peers) — value vs value, same stage and era.
Active
  • Last raise 19 mo ago; this sector typically re-raises about every 15 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotech / Pharma

Asset Blue Pharmacy Services, Inc. is one of 227 Biotech / Pharma companies tracked from CHICAGO. By capital raised it ranks in the upper tier (ahead of 88% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
4
Investors (latest)
2021
Year incorporated
2024-11-26
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeed · 2021-08-24 Raised $3.0M (real) Modeled valuation $67M (est)$3.0M$67MSeed2021Series B · 2022-01-14 Raised $28M (real) Modeled valuation $537M (est)$28M$537MSeries B2022Series B · 2024-11-26 Raised $18M (real) Modeled valuation $105M (est)$18M$105MSeries B2024+$28M+$18MCumulative $48M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$3.0M · 2021
Series B$27.5M · 2022no Series A on file
Series B extension$17.5M · 2024

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$104.7M
Base estimate est.
$35.9M
Conservative case
$173.5M
Upside case
$97.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech/pharma sector profile. Directional, not a quoted figure.

Seed · modeled $66.7M · 2021-08-242021Series B · modeled $536.6M · 2022-01-14Series B · modeled $104.7M · 2024-11-262024
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
56%
Survival probability
37% low · 68% high
1.51×/yr
Annual markup
1.83×/yr upside case
1.6 yr
Elapsed time used
1.6 yr actual, capped for stale marks
biotech/pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
20 mo
Avg between rounds
$14.7M/yr
Capital velocity
4.9 yr
On record since
2021
First round
3
Rounds on file
How it compares to the market

Benchmarked against 227 companies in Biotech / Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 8.5× above median
This company$48.0M
Sector median$5.6M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.9× of median
This company$17.5M
Sector median$18.7M
Modeled value — vs sector median (estimate, all stages) 3.4× above median
This company$104.7M
Sector median$30.5M

Raised more than 88% of sector peers (real $). Modeled value above 70% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #14 of 15.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)Carbon Biosciences, Inc. · Series B Raised $38.0M · modeled $744.8M (est)Slingshot Biosciences, Inc. · Series B Raised $49.1M · modeled $335.1M (est)Nueva Bio LLC · Series B Raised $17.5M · modeled $319.2M (est)Telesis Bio Inc. · Series B Raised $28.0M · modeled $308.2M (est)Turn Biotechnologies, Inc. · Series B Raised $29.1M · modeled $293.6M (est)Surf Bio, Inc. · Series B Raised $16.0M · modeled $287.9M (est)Prellis Biologics, Inc · Series B Raised $47.3M · modeled $277.2M (est)Appello Pharmaceuticals, Inc. · Series B Raised $29.0M · modeled $263.7M (est)Protillion Biosciences, lnc. · Series B Raised $19.0M · modeled $256.6M (est)Orange Grove Bio LLC · Series B Raised $16.6M · modeled $255.9M (est)Ganymede Bio, Inc. · Series B Raised $15.2M · modeled $238.9M (est)Q Bio, Inc. · Series B Raised $27.1M · modeled $213.8M (est)Asset Blue Pharmacy Services, Inc. (this company) Raised $48.0M · modeled $104.7M (est)Asset Blue Pharmacy Services, Inc.
CompanyStageRaised · realValue · estvs peer med.
Carbon Biosciences, Inc.Series B$38.0M$744.8M2.82×
Slingshot Biosciences, Inc.Series B$49.1M$335.1M1.27×
Nueva Bio LLCSeries B$17.5M$319.2M1.21×
Telesis Bio Inc.Series B$28.0M$308.2M1.17×
Turn Biotechnologies, Inc.Series B$29.1M$293.6M1.11×
Surf Bio, Inc.Series B$16.0M$287.9M1.09×
Prellis Biologics, IncSeries B$47.3M$277.2M1.05×
Appello Pharmaceuticals, Inc.Series B$29.0M$263.7M1.00×
Protillion Biosciences, lnc.Series B$19.0M$256.6M0.97×
Orange Grove Bio LLCSeries B$16.6M$255.9M0.97×
Ganymede Bio, Inc.Series B$15.2M$238.9M0.91×
Q Bio, Inc.Series B$27.1M$213.8M0.81×
Asset Blue Pharmacy Services, Inc. this companySeries B$48.0M$104.7M0.40×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$3.0M2021-08-24$15.0M$66.7M90%
Series B$27.5M2022-01-14$152.8M$536.6M90%
Series B$17.5M2024-11-26$97.2M$104.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$3.0M2021-08-24
    • First recorded raise — entered as Seed.
    • 2 investors on this round.
  2. Series B$27.5M2022-01-14
    • Came back fast: 5 mo vs the ~15 mo sector norm.
    • Round 9.2× larger than the prior — scaling up.
    • 3 investors on this round.
  3. Series B$17.5M2024-11-26
    • Raised again after 34 mo — slower than the ~15 mo sector norm.
    • Round 1.6× smaller than the prior — bridge or down round.
    • 4 investors on this round.
Intelligence
2026 ~Q3
Modeled next raise · ~20mo cadence
$17.5M
Modeled next size est.range $17.5M$28.0M
0.6×
Last step-up
$14.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Lynne Chou O'Keefe6 other2024-11
Benjamin Robbins4 other2022-01
Jeffrey Park2024-11
Jonathon Thierer2021-08
Mark Thierer2021-08
Registry & provenance

Asset Blue Pharmacy Services, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1880783
SEC CIK
2021
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Prellis Biologics, IncBiotech / PharmaSeries B$47.3M$277.2Msame sector · same stage
Slingshot Biosciences, Inc.Biotech / PharmaSeries B$49.1M$335.1Msame sector · same stage
Arpeggio Biosciences, Inc.Biotech / PharmaSeries B$46.4M$80.7Msame sector · same stage
Front Range Biosciences, Inc.Biotech / PharmaSeries B$45.0M$689.5Msame sector · same stage
Bird Rock Bio, Inc.Biotech / PharmaSeries B$52.5M$91.9Msame sector · same stage
Abrexa Pharmaceuticals, Inc.Biotech / PharmaSeries B$40.1M$118.2Msame sector · same stage
Arcadia Biosciences, Inc.Biotech / PharmaSeries B$58.4M$7.8Msame sector · same stage
Wheeler Bio, Inc.Biotech / PharmaSeries B$59.9M$123.8Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
BlueSphere Bio, Inc.Biotech / PharmaSeries C$1.5B84%
Key Biologics Holdings, LLCBiotech / PharmaSeries A$167.5M81%
Blue Note Therapeutics, Inc.PharmaSeries A$309.4M81%
Remote Pharmacy LLCBiotech / PharmaPre-Seed$2.1M80%
WPD Pharmaceuticals Inc.Biotech / PharmaSeries B$32.7M80%
PharmaCCX, Inc.Biotech / PharmaSeries A$45.1M79%
Bluestone Biomedical Group LLCOtherSeries A$151.3M79%
Pillar Biosciences Inc.Biotech / PharmaSeries B$511.7M79%
Frequently asked
How much funding has Asset Blue Pharmacy Services, Inc. raised?
Asset Blue Pharmacy Services, Inc. has raised approximately $48.0M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Asset Blue Pharmacy Services, Inc.'s estimated valuation?
Provath's modeled valuation for Asset Blue Pharmacy Services, Inc. is approximately $104.7M (modeled range $35.9M–$173.5M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Asset Blue Pharmacy Services, Inc. at?
Asset Blue Pharmacy Services, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Tue Nov 26.
What does Asset Blue Pharmacy Services, Inc. do and where is it based?
Asset Blue Pharmacy Services, Inc. operates in the Biotech / Pharma sector, based in CHICAGO.
Explore related

See where Asset Blue Pharmacy Services, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Asset Blue Pharmacy Services, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.